NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD
Kintara Therapeutics, Inc. (KTRA) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 3 recommend buying, 1 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
